Ashley Gallagher, MA

The decision represents the first new sunscreen ingredient permitted in the United States since the late 1990s.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Medicare’s $35 insulin cap cuts cost swings, boosts adherence for high-burden patients, and highlights pharmacists’ role in preventing rationing.

BA.3.2 variant spreads globally, testing vaccine matches as the FDA backs XFG immunizations.

The Age-Friendly Pharmacy certification and the 4Ms reshape senior care, teamwork, and deprescribing by putting the patient in the center of care.

Alabama bans research-grade peptides for patients amid FDA reviewing 12 peptides for compounding use.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

Federal court blocks abrupt childhood vaccine schedule changes, raising insurance and liability uncertainty as pharmacies navigate shifting guidance and growing parent hesitancy.

The executive order calls to realign core childhood vaccine recommendations with scientific evidence and best practices of peer, developed nations.

Bepirovirsen suggests that a finite 24-week treatment course can achieve a functional cure defined as sustained undetectable hepatitis B surface antigen.

Pharmacists flag risky medications, safeguard cold-chain supplies, and counsel with the HEAT checklist.

Pharmacists help women choose safer hormone replacement therapy or nonhormonal relief options.

The approval arrives prior to the Prescription Drug User Fee Act action date of June 16, 2026.

Older adults with type 2 diabetes often juggle 5 or more different prescriptions.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

Pharmacies can build clinical workflows, bill like providers, and get paid for MTM and test-and-treat services patients value.

FDA updates Tremfya label in psoriatic arthritis, confirming it slows structural joint damage and helping patients protect mobility while easing symptoms.

New FDA label lets linaclotide treat functional constipation in children 2 to 5, with dosing tips, mixing options, and key safety warnings.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

American College of Cardiology's new postpartum cardiovascular disease pathway urges early follow-up and tighter blood pressure goals.

The FDA clears Hepcludex, the first chronic hepatitis D therapy, offering new hope with strong viral suppression data and key safety monitoring needs.

An open line of communication between care teams is key to improving patient outcomes.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

Late-phase trials show switching to daily oral orforglipron or lower-dose tirzepatide helps maintain weight loss, easing regain and boosting adherence.

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Controlling symptoms of allergy and asthma helps patients improve quality of life.

New FDA guidance sharpens postmarket pregnancy drug safety data, improving labels and empowering pharmacists to report adverse events.

New OASIS 4 data show early oral semaglutide responders hit 21.6% weight loss and improve mobility.

Declining Black-owned pharmacies reshape community care, and pharmacists can advance health equity today.

The announcement comes with a partnership with Mark Cuban Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.